Shots:
- Dr. Reddy’s & Henlius have entered into a license agreement to develop & market HLX15, biosimilar version of Darzalex & Darzalex Faspro (daratumumab)
- As per the agreement, Dr. Reddy’s will get exclusive rights to market HLX15 (SC & IV) in the US & EU in exchange for ~$131.6M ($33M upfront + milestones), plus net sales-based royalties, while Henlius will handle HLX15’s development, manufacturing & commercial supply
- Daratumumab (SC & IV) is an anti-CD38 fully human mAb indicated for the treatment of pts with multiple myeloma
Ref: Dr. Reddy’s | Image: Dr. Reddy’s & Henlius
Related News:- Dr. Reddy’s Ituxredi (Biosimilar, MabThera) Receives the CHMP’s Positive Opinion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
